Kovitz Investment Group Partners LLC Purchases Shares of 2,431 Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Kovitz Investment Group Partners LLC purchased a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 2,431 shares of the biopharmaceutical company’s stock, valued at approximately $669,000.

A number of other hedge funds also recently bought and sold shares of the stock. Sphera Funds Management LTD. acquired a new stake in Alnylam Pharmaceuticals in the 3rd quarter valued at about $1,925,000. SYM FINANCIAL Corp raised its position in Alnylam Pharmaceuticals by 6.2% in the 3rd quarter. SYM FINANCIAL Corp now owns 947 shares of the biopharmaceutical company’s stock valued at $260,000 after purchasing an additional 55 shares in the last quarter. Quantinno Capital Management LP raised its position in Alnylam Pharmaceuticals by 50.3% in the 3rd quarter. Quantinno Capital Management LP now owns 3,366 shares of the biopharmaceutical company’s stock valued at $926,000 after purchasing an additional 1,126 shares in the last quarter. Parkman Healthcare Partners LLC acquired a new stake in Alnylam Pharmaceuticals in the 3rd quarter valued at about $7,009,000. Finally, Ikarian Capital LLC acquired a new stake in Alnylam Pharmaceuticals in the 3rd quarter valued at about $2,404,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on ALNY. Canaccord Genuity Group increased their price target on Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the company a “buy” rating in a research report on Friday, November 1st. StockNews.com lowered Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, November 28th. Barclays raised their target price on Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the stock an “overweight” rating in a research report on Friday, November 1st. Needham & Company LLC reissued a “buy” rating and set a $320.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st. Finally, Wolfe Research lowered Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a research report on Tuesday, November 12th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and eighteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $298.09.

Alnylam Pharmaceuticals Trading Down 3.5 %

Shares of ALNY stock opened at $245.26 on Friday. The business’s 50 day moving average is $267.46 and its two-hundred day moving average is $247.48. Alnylam Pharmaceuticals, Inc. has a twelve month low of $141.98 and a twelve month high of $304.39. The company has a market capitalization of $31.63 billion, a P/E ratio of -93.61 and a beta of 0.32. The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 31.64.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The business had revenue of $500.90 million during the quarter, compared to the consensus estimate of $532.91 million. During the same quarter in the prior year, the business earned $1.15 EPS. The company’s revenue was down 33.3% on a year-over-year basis. Equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -2.21 EPS for the current year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CMO Pushkal Garg sold 1,682 shares of the business’s stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total transaction of $422,148.36. Following the sale, the chief marketing officer now directly owns 17,457 shares in the company, valued at approximately $4,381,357.86. The trade was a 8.79 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Tolga Tanguler sold 1,469 shares of the business’s stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total value of $368,689.62. Following the sale, the executive vice president now owns 13,191 shares in the company, valued at approximately $3,310,677.18. The trade was a 10.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 8,370 shares of company stock worth $2,100,703. 1.50% of the stock is currently owned by insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.